Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) | test |
Test |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
sfgd |
Partnerships |
Events |
Jobs |
Senex BiotechnologyThe mission of Senex Biotechnology is to discover and develop therapeutic agents to effectively treat cancer, viral diseases and age-related diseases, such as Alzheimer's, renal disease, atherosclerosis, and arthritis, by targeting damage-inducible... View all JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
